

ORLY^{20 capsules}_{slim}

for optimal obesity management

Composition:

Each capsule contains:

Orlistat 120 mg

Properties:

ORLY_{slim} capsule contains the lipase inhibitor Orlistat used for the management of obesity in conjunction with a reduced-calorie diet. Orlistat reduces the absorption of dietary fat through inactivation of gastric and pancreatic lipases in the stomach and small intestine, consequently, the dietary fat remains in the form of undigested triglycerides, and is not further hydrolyzed into absorbable fatty acids and monoglycerides, this results in lowering of calorie production and leads to an effective weight control.

Indications:

- For management of weight loss and weight control for adults and adolescents.
- For reduction of weight regain liability post a weight loss attainment.

Dosage:

Adult dose: one 120 mg capsule to be taken immediately before each principal meal (up to a maximum of 360 mg daily); It may be taken also during meals, or up to 1 hour after meals, the dose is omitted if missed or the meal is fat-free.

Treatment may extend for a period longer than 12 weeks when a 5% weight loss is achieved during this period as measured from initial therapy.

- **ORLY_{slim}** is not recommended for children

Precautions:

- Organic causes of obesity (such as hypothyroidism) should be excluded.
- Gastrointestinal related symptoms may increase when **ORLY_{slim}** is taken with a fatty meal.

- No sufficient studies are available for pregnancy so it should not be used during pregnancy or by nursing women.
- **ORLY_{slim}** capsule is prescribed with caution to patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.

Side-effects:

- Oily discharge from rectum, flatulence, faecal urgency, liquid or oily stools, faecal incontinence, abdominal distension and pain (gastro-intestinal effects last for few weeks and are minimized by reduced fat intake).
- Less frequent side effects which appear only after long period of therapy are tooth and gingival disorders; respiratory infections; anxiety, headache; menstrual disturbances, urinary-tract infection.

Contra-indications:

Chronic malabsorption syndrome, cholestasis and breast-feeding .

Drug-drug interaction:

- Orlistat possibly reduces plasma concentration of amiodarone and absorption of cyclosporin.
- Avoid concomitant use with acarbose .
- Monitoring of anticoagulant effect of coumarins should be done if used with orlistat.
- Orlistat may impair absorption of fat-soluble vitamins.

Storage:

- Store at a temperature not exceeding 30°C.

Package:

Boxes of one or two blisters each of 10 capsules .



EVA PHARMA

For Pharmaceuticals & Medical Appliances S.A.E
Kafri El Qahal - Haram - Giza - Egypt

C1287.00/01/00